Soluble B-cell maturation antigen in multiple myeloma.

Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Publication: New York Ny : Wiley-Blackwell
Original Publication: New York, Liss.

Multiple Myeloma*/pathology ; Antibodies, Bispecific*/therapeutic use; Humans ; B-Cell Maturation Antigen ; Immunotherapy, Adoptive ; Amyloid Precursor Protein Secretases

B-cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma-secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme-linked immunosorbent assays, as well as through mass spectrometry-based proteomics. Besides its short serum half-life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti-myeloma therapies. In short, sBCMA might be the "Swiss army knife" of MM laboratory testing, but is it ready for prime time?
(© 2024 Wiley Periodicals LLC.)

Bera TK. Anti-BCMA immunotoxins: design, production, and preclinical evaluation. Biomolecules. 2020;10(10):1387. doi:10.3390/biom10101387.
Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol OncolJ Hematol Oncol. 2020;13(1):125. doi:10.1186/s13045-020-00962-7.
Anderson LD, Dhakal B, Jain T, et al. Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(1):17-37. doi:10.1016/j.jtct.2023.10.022.
Sadek NL, Costa BA, Nath K, Mailankody S. CAR T-cell therapy for multiple myeloma: a clinical practice-oriented review. Clin Pharmacol Ther. 2023;114(6):1184-1195. doi:10.1002/cpt.3057.
Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801-e812. doi:10.1016/S2352-3026(23)00243-0.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002-1014. doi:10.1056/NEJMoa2213614.
San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379.
Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting. J Hematol OncolJ Hematol Oncol. 2023;16(1):92. doi:10.1186/s13045-023-01489-3.
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005. doi:10.1038/s41375-020-0734-z.
Alomari M, Kunacheewa C, Manasanch EE. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leuk Lymphoma. 2023;64(2):261-272. doi:10.1080/10428194.2022.2133540.
Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396-410. doi:10.1016/j.ccell.2017.02.002.
Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225-3236. doi:10.1182/blood-2016-01-691162.
Bu DX, Singh R, Choi EE, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9(40):25764-25780. doi:10.18632/oncotarget.25359.
Quazi S. An overview of CAR T cell mediated B cell maturation antigen therapy. Clin Lymphoma Myeloma Leuk. 2022;22(6):e392-e404. doi:10.1016/j.clml.2021.12.003.
Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19(11):1143-1156. doi:10.1080/14712598.2019.1641196.
Palm AKE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol. 2019;10:1787. doi:10.3389/fimmu.2019.01787.
Wang Y, Li C, Xia J, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021;5(23):5290-5299. doi:10.1182/bloodadvances.2021004603.
Zhang M, Gray F, Cushman I, et al. A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma. Mod Pathol. 2023;36(4):100050. doi:10.1016/j.modpat.2022.100050.
Dogan A, Siegel D, Tran N, et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 2020;10(6):73. doi:10.1038/s41408-020-0337-y.
Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585-1597. doi:10.1182/blood.2019000050.
Li D, Que Y, Ding S, et al. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report. J Immunother Cancer. 2022;10(9):e005403. doi:10.1136/jitc-2022-005403.
Laurent SA, Hoffmann FS, Kuhn PH, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333. doi:10.1038/ncomms8333.
Sanchez E, Gillespie A, Tang G, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22(13):3383-3397. doi:10.1158/1078-0432.CCR-15-2224.
Chen H, Yu T, Lin L, et al. γ-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12(8):118. doi:10.1038/s41408-022-00716-3.
Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785-795. doi:10.3324/haematol.2016.150896.
Chen H, Li M, Xu N, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62-66. doi:10.1016/j.leukres.2019.04.008.
Schmidts A, Ormhøj M, Choi BD, et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019;3(21):3248-3260. doi:10.1182/bloodadvances.2019000703.
Lee H, Durante M, Ahn S, et al. The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma. Blood. 2023;142(Supplement 1):4688. doi:10.1182/blood-2023-188080.
Sanchez E, Smith EJ, Yashar MA, et al. The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in. Multiple Myeloma Target Oncol. 2018;13(1):39-47. doi:10.1007/s11523-017-0538-x.
Stauffer A, Ray C, Hall M. A flexible multiplatform bioanalytical strategy for measurement of Total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug. Assay Drug Dev Technol. 2021;19(1):17-26. doi:10.1089/adt.2020.1024.
Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727-738. doi:10.1111/j.1365-2141.2012.09241.x.
Jew S, Bujarski S, Soof C, et al. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br J Haematol. 2021;192(6):1064-1067. doi:10.1111/bjh.16673.
Migkou M, Avivi I, Gavriatopoulou M, et al. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Ann Hematol. 2020;99(6):1251-1255. doi:10.1007/s00277-020-03984-w.
Bujarski S, Udd K, Soof C, et al. Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed/refractory multiple myeloma starting new therapy. Target Oncol. 2021;16(4):503-515. doi:10.1007/s11523-021-00821-6.
Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015;95(1):57-64. doi:10.1111/ejh.12478.
Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6.
Van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827-832. doi:10.1182/blood-2007-01-067728.
Bujarski S, Udd K, Soof C, et al. Baseline and increases in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among relapsed/refractory multiple myeloma patients undergoing new treatments. Blood. 2019;134(Supplement_1):1786. doi:10.1182/blood-2019-132012.
Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12(9):133. doi:10.1038/s41408-022-00732-3.
Visram A, Soof C, Rajkumar SV, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120. doi:10.1038/s41408-021-00505-4.
Wiedemann Á, Szita VR, Horváth R, et al. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma. Pathol Oncol Res. 2023;29:1611171. doi:10.3389/pore.2023.1611171.
Jew S, Bujarski S, Regidor B, et al. Clinical outcomes and serum B-cell maturation antigen levels in a real-world unselected population of newly diagnosed multiple myeloma patients. Target Oncol. 2023;18(5):735-747. doi:10.1007/s11523-023-00990-6.
Tan W, Kunacheewa C, Becnel M, et al. OA-36 SBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies. Clin Lymphoma Myeloma Leuk. 2023;23:S22. doi:10.1016/S2152-2650(23)01603-8.
Terpos E, Ntanasis-Stathopoulos I, Malandrakis P, et al. P-167 serum BCMA levels evaluated by Elecsys sBCMA assay at diagnosis have prognostic value in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:S127-S128. doi:10.1016/S2152-2650(23)01785-8.
Elmeliegy M, Kei Lon H, Wang D, et al. Soluble B-cell maturation antigen As a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from Elranatamab (ELRA) Magnetismm studies. Blood. 2023;142(Supplement 1):3345. doi:10.1182/blood-2023-190341.
Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850.
Shen Y, Liu J, Wang B, et al. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr Res Transl Med. 2023;71(2):103378. doi:10.1016/j.retram.2023.103378.
Lowther DE, Houseman EA, Han G, et al. No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 trials of patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2022;140(Supplement 1):611-613. doi:10.1182/blood-2022-157767.
Lin Y, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286-2294. doi:10.1038/s41591-023-02496-0.
Rodríguez-Otero P, Shah N, Munshi N, et al. P19: baseline correlates of complete response to IDECABTAGENE VICLEUCEL (ide-CEL, BB2121), a BCMA-directed car t cell therapy in patients with relapsed and refractory multiple myeloma: SUBANALYSIS of the KARMMA trial. HemaSphere. 2022;6:21-22. doi:10.1097/01.HS9.0000829648.85784.e2.
Piasecki J, Desai K, Courtney C, et al. Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8031. doi:10.1200/JCO.2023.41.16_suppl.8031.
Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol OncolJ Hematol Oncol. 2022;15(1):86. doi:10.1186/s13045-022-01301-8.
Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219-230. doi:10.1182/blood.2022015526.
Piasecki J, Devries T, Radhakrishnan A, et al. Association of Baseline and Postinfusion Biomarkers with safety and efficacy endpoints in patients treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the phase 1/2 Evolve study (NCT03430011). Blood. 2020;136(Supplement 1):2-3. doi:10.1182/blood-2020-137786.
Cowan AJ, Pont MJ, Sather BD, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811-822. doi:10.1016/S1470-2045(23)00246-2.
Girgis S, Wang Lin SX, Pillarisetti K, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Adv. 2023;7(4):644-648. doi:10.1182/bloodadvances.2022007625.
Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570-2576. doi:10.1038/s41591-023-02589-w.
Boyapati A, Richter J, Suvannasankha A, et al. P-005 association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2023;23:S35. doi:10.1016/S2152-2650(23)01623-3.
Bujarski S, Sutanto C, Spektor TM, et al. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol. 2022;40(2):243-248. doi:10.1002/hon.2961.
Dekhtiarenko I, Attig J, Helms HJ, et al. P-006 SBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD. Clin Lymphoma Myeloma Leuk. 2023;23:S35-S36. doi:10.1016/S2152-2650(23)01624-5.
Kumar S, Rajkumar SV. Surrogate endpoints in randomised controlled trials: a reality check. The Lancet. 2019;394(10195):281-283. doi:10.1016/S0140-6736(19)31711-8.
Da Vià MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616-619. doi:10.1038/s41591-021-01245-5.
Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868. doi:10.1038/s41467-021-21177-5.
Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295-2306. doi:10.1038/s41591-023-02491-5.
Samur MK, Aktas Samur A, Corre J, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7(21):6599-6603. doi:10.1182/bloodadvances.2023010025.
Cattaneo I, Valgardsdottir R, Cavagna R, et al. Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: a case report. Br J Haematol. 2023;1-5. doi:10.1111/bjh.19168.
Zhou X, Rasche L, Kortüm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2022;108(4):958-968. doi:10.3324/haematol.2020.266841.

American Society of Hematology

0 (B-Cell Maturation Antigen)
0 (Antibodies, Bispecific)
EC 3.4.- (Amyloid Precursor Protein Secretases)

Date Created: 20240125 Date Completed: 20240319 Latest Revision: 20240726

20240727

10.1002/ajh.27225

38270277